SyntheticMR AB (publ), a global leader in quantitative MRI software, today announced continued portfolio and commercial progress following its acquisition of Combinostics Oy in early 2025.
The integration has established SyntheticMR as one unified company with a broader offering and a strengthened position in the growing neurodegenerative disease imaging segment.
cNeuro® cMRI has been integrated into SyntheticMR's product portfolio, expanding the company's capabilities in quantitative and AI-driven neuroimaging. Together with SyMRI®, the combined portfolio delivers comprehensive quantitative brain imaging solutions for patients with neurological disorders.
Following the acquisition, SyntheticMR has obtained regulatory approval in Europe for targeted updates to cNeuro® cMRI, including functionality for the automated detection of side effects associated with disease-modifying therapies for Alzheimer's disease, known as ARIA (Amyloid-Related Imaging Abnormalities). This responds to emerging clinical needs driven by the increasing adoption of anti-amyloid therapies in Alzheimer's disease.
As MRI imaging volumes rise, cNeuro® cMRI with automated ARIA detection supports clinicians by improving workflow efficiency, strengthening diagnostic confidence, and enabling faster identification of ARIA in clinical practice.
In parallel, cNeuro® cMRI has been introduced in the Indian market, leveraging its established SyMRI® presence to expand in a key growth region.
"The acquisition of Combinostics has enabled us to operate as one stronger organization with a broader portfolio." said Lena Åredal, CEO of SyntheticMR. "By aligning expertise across the company, we are strengthening our offering and positioning SyntheticMR as a leading provider of comprehensive solutions in neurodegenerative imaging."
SyntheticMR remains focused on innovation, regulatory expansion, and commercial execution to meet evolving clinical needs and drive sustainable long-term growth.